Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$37.2 million","upfrontCash":"Undisclosed","newsHeadline":"OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"company":"OliX Pharmaceutical","sponsor":"KB Investment","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"}]

OliX Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars

Details:

OLX10010 (compound name of OLX101A), a drug that targets connective tissue growth factor, is in phase 2 development as a treatment for hypertrophic scar.

Lead Product(s): OLX10010

Therapeutic Area: Dermatology Product Name: OLX101A

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 07, 2022

ASK
US

Upload
your Pipeline Activity

OliX Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement

Details:

The capital will be used to finance R&D activities. The Company’s dry and wet AMD (OLX301A/OLX10010) and androgenic alopecia (OLX104C) programs are also planned to be entered into clinical trials, followed by HBV (OLX703A) and nonalcoholic steatohepatitis (OLX702A).

Lead Product(s): OLX10010

Therapeutic Area: Dermatology Product Name: OLX101A

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: KB Investment

Deal Size: $45.0 million Upfront Cash: Undisclosed

Deal Type: Financing May 27, 2022

ASK
US

Upload
your Pipeline Activity

OliX Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally

Details:

Capital will fund construction of RNA synthesis GMP facility in San Diego to advance the company’s core pipeline, including OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis.

Lead Product(s): OLX101A

Therapeutic Area: Dermatology Product Name: OLX101A

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $37.2 million Upfront Cash: Undisclosed

Deal Type: Financing December 01, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY